Facial Plast Surg 2012; 28(05): 504-512
DOI: 10.1055/s-0032-1325644
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Current Concepts in the Etiology and Treatment of Keloids

Michelle C. Naylor
1   Bobby R. Alford Department of Otolaryngology–Head and Neck Surgery, Baylor College of Medicine, Houston, Texas
,
Anthony E. Brissett
1   Bobby R. Alford Department of Otolaryngology–Head and Neck Surgery, Baylor College of Medicine, Houston, Texas
2   Department of Facial Plastic and Reconstructive Surgery, Baylor Facial Plastic Surgery Center, Baylor College of Medicine, Houston, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
01 October 2012 (online)

Abstract

Keloids are benign, fibroproliferative growths that occur as a result of dermal injury in ~15% of the population. They are characterized by their extension beyond the confines of the original injury and often present with pain and pruritus. Additionally, these growths may result in cosmetic deformities and contribute to significant emotional distress. It is thought that keloids form as a result of aberrancies in the normal wound-healing process, which is complex and involves an elegant interplay between multiple cell types, cytokines, and proteins. The exact etiology is unknown, but significant research efforts have been made. These efforts have revealed that various cell types in keloids are either hyperresponsive and/or overproductive of various growth factors. Additionally, keloid cell types respond differently to mechanical strain than skin cells in patients who do not form keloids. This lack of understanding of keloid pathophysiology has left the care provider with a lack of a single definitive treatment strategy. Instead, a multitude of therapies exist ranging from surgery to injectables to lasers and any combination thereof. This purpose of this article is to highlight our current knowledge and emerging scientific understanding of keloid pathology and the current management strategies.

 
  • References

  • 1 Brissett AE, Sherris DA. Scar contractures, hypertrophic scars, and keloids. Facial Plast Surg 2001; 17: 263-272
  • 2 Alibert JLM. Note sur la keloide. J Univ Sci Med 1816; 2: 207-216
  • 3 Alhady SM, Sivanantharajah K. Keloids in various races. A review of 175 cases. Plast Reconstr Surg 1969; 44: 564-566
  • 4 Atiyeh BS, Costagliola M, Hayek SN. Keloid or hypertrophic scar: the controversy: review of the literature. Ann Plast Surg 2005; 54: 676-680
  • 5 Butler PD, Longaker MT, Yang GP. Current progress in keloid research and treatment. J Am Coll Surg 2008; 206: 731-741
  • 6 Murray JC. Keloids and hypertrophic scars. Clin Dermatol 1994; 12: 27-37
  • 7 Cosman B, Crikelair G, Gaulin JEA. The surgical treatment of keloids. Plast Reconstr Surg 1961; 27: 335-358
  • 8 Bloom D. Heredity of keloids; review of the literature and report of a family with multiple keloids in five generations. N Y State J Med 1956; 56: 511-519
  • 9 Marneros AG, Norris JE, Olsen BR, Reichenberger E. Clinical genetics of familial keloids. Arch Dermatol 2001; 137: 1429-1434
  • 10 Marneros AG, Norris JE, Watanabe S, Reichenberger E, Olsen BR. Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11. J Invest Dermatol 2004; 122: 1126-1132
  • 11 Lee SS, Yosipovitch G, Chan YH, Goh CL. Pruritus, pain, and small nerve fiber function in keloids: a controlled study. J Am Acad Dermatol 2004; 51: 1002-1006
  • 12 Lindsey WH, Davis PT. Facial keloids. A 15-year experience. Arch Otolaryngol Head Neck Surg 1997; 123: 397-400
  • 13 Kelly AP. Medical and surgical therapies for keloids. Dermatol Ther 2004; 17: 212-218
  • 14 Ramakrishnan KM, Thomas KP, Sundararajan CR. Study of 1,000 patients with keloids in South India. Plast Reconstr Surg 1974; 53: 276-280
  • 15 Wolfram D, Tzankov A, Pulzl P, Piza-Katzer H. Hypertrophic scars and keloids—a review of their pathophysiology, risk factors, and therapeutic management. Am Soc Dermatol Surg 2009; 35: 171-181
  • 16 Meenakshi JV, Ramakrishnan KM, Babu M. Keloids and hypertrophic scars: a review. Indian J Plast Surg 2005; 38: 175-179
  • 17 Ehrlich HP, Desmoulière A, Diegelmann RF , et al. Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol 1994; 145: 105-113
  • 18 Amadeu T, Braune A, Mandarim-de-Lacerda C, Porto LC, Desmoulière A, Costa A. Vascularization pattern in hypertrophic scars and keloids: a stereological analysis. Pathol Res Pract 2003; 199: 469-473
  • 19 Kischer CW, Shetlar MR. Collagen and mucopolysaccharides in the hypertrophic scar. Connect Tissue Res 1974; 2: 205-213
  • 20 Lee JY, Yang CC, Chao SC, Wong TW. Histopathological differential diagnosis of keloid and hypertrophic scar. Am J Dermatopathol 2004; 26: 379-384
  • 21 Igarashi A, Nashiro K, Kikuchi K , et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 1996; 106: 729-733
  • 22 Haisa M, Okochi H, Grotendorst GR. Elevated levels of PDGF alpha receptors in keloid fibroblasts contribute to an enhanced response to PDGF. J Invest Dermatol 1994; 103: 560-563
  • 23 Xia W, Longaker MT, Yang GP. P38 MAP kinase mediates transforming growth factor-beta2 transcription in human keloid fibroblasts. Am J Physiol Regul Integr Comp Physiol 2006; 290: R501-R508
  • 24 Chin GS, Liu W, Peled Z , et al. Differential expression of transforming growth factor-beta receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast Reconstr Surg 2001; 108: 423-429
  • 25 Xia W, Kong W, Wang Z , et al. Increased CCN2 transcription in keloid fibroblasts requires cooperativity between AP-1 and SMAD binding sites. Ann Surg 2007; 246: 886-895
  • 26 Sandulache VC, Parekh A, Li-Korotky H, Dohar JE, Hebda PA. Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis. Wound Repair Regen 2007; 15: 122-133
  • 27 Lim IJ, Phan TT, Song C, Tan WT, Longaker MT. Investigation of the influence of keloid-derived keratinocytes on fibroblast growth and proliferation in vitro. Plast Reconstr Surg 2001; 107: 797-808
  • 28 Boyce ST. Epidermis as a secretory tissue. J Invest Dermatol 1994; 102: 8-10
  • 29 Xia W, Phan TT, Lim IJ, Longaker MT, Yang GP. Complex epithelial-mesenchymal interactions modulate transforming growth factor-beta expression in keloid-derived cells. Wound Repair Regen 2004; 12: 546-556
  • 30 Xia W, Phan TT, Lim IJ, Longaker MT, Yang GP. Differential transcriptional responses of keloid and normal keratinocytes to serum stimulation. J Surg Res 2006; 135: 156-163
  • 31 Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994; 1: 71-81
  • 32 Wang JF, Jiao H, Stewart TL, Shankowsky HA, Scott PG, Tredget EE. Fibrocytes from burn patients regulate the activities of fibroblasts. Wound Repair Regen 2007; 15: 113-121
  • 33 Chesney J, Bacher M, Bender A, Bucala R. The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc Natl Acad Sci U S A 1997; 94: 6307-6312
  • 34 Hartlapp I, Abe R, Saeed RW , et al. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J 2001; 15: 2215-2224
  • 35 Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001; 166: 7556-7562
  • 36 Naylor MC, Lazar DA, Zamora IJ , et al. Increased in vitro differentiation of fibrocytes from keloid patients is inhibited by serum amyloid P. Wound Repair Regen 2012; 20: 277-283
  • 37 Ghahary A, Shen YJ, Nedelec B, Wang R, Scott PG, Tredget EE. Collagenase production is lower in post-burn hypertrophic scar fibroblasts than in normal fibroblasts and is reduced by insulin-like growth factor-1. J Invest Dermatol 1996; 106: 476-481
  • 38 Tanaka A, Hatoko M, Tada H, Iioka H, Niitsuma K, Miyagawa S. Expression of p53 family in scars. J Dermatol Sci 2004; 34: 17-24
  • 39 Saed GM, Ladin D, Olson J, Han X, Hou Z, Fivenson D. Analysis of p53 gene mutations in keloids using polymerase chain reaction-based single-strand conformational polymorphism and DNA sequencing. Arch Dermatol 1998; 134: 963-967
  • 40 Chen BP, Li YS, Zhao Y , et al. DNA microarray analysis of gene expression in endothelial cells in response to 24-h shear stress. Physiol Genomics 2001; 7: 55-63
  • 41 Chiquet M. Regulation of extracellular matrix gene expression by mechanical stress. Matrix Biol 1999; 18: 417-426
  • 42 Lin K, Hsu PP, Chen BP , et al. Molecular mechanism of endothelial growth arrest by laminar shear stress. Proc Natl Acad Sci U S A 2000; 97: 9385-9389
  • 43 Wang Z, Fong KD, Phan TT, Lim IJ, Longaker MT, Yang GP. Increased transcriptional response to mechanical strain in keloid fibroblasts due to increased focal adhesion complex formation. J Cell Physiol 2006; 206: 510-517
  • 44 Chike-Obi CJ, Cole PD, Brissett AE. Keloids: pathogenesis, clinical features, and management. Semin Plast Surg 2009; 23: 178-184
  • 45 Alster TS, Tanzi EL. Hypertrophic scars and keloids: etiology and management. Am J Clin Dermatol 2003; 4: 235-243
  • 46 Darougheh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Clin Exp Dermatol 2007; 34: 219-223
  • 47 Chen MA, Davidson TM. Scar management: prevention and treatment strategies. Curr Opin Otolaryngol Head Neck Surg 2005; 13: 242-247
  • 48 Mustoe TA, Cooter RD, Gold MH , et al; International Advisory Panel on Scar Management. International clinical recommendations on scar management. Plast Reconstr Surg 2002; 110: 560-571
  • 49 Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg 1999; 104: 1435-1458
  • 50 Tan KT, Shah N, Pritchard SA, McGrouther DA, Bayat A. The influence of surgical excision margins on keloid prognosis. Ann Plast Surg 2010; 64: 55-58
  • 51 Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002; 47 (4 Suppl) S209-S211
  • 52 Berman B, Duncan MR. Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Dermatol 1989; 21 (4 Pt 1) 694-702
  • 53 Jackson I, Bhageshpur R, DiNick V, Khan A, Bhaloo S. Investigation of recurrence rates among earlobe keloids utilizing various postoperative therapeutic modalities. Eur J Plast Surg 2001; 24: 88-95
  • 54 De Beurmann R, Gougerot H. Cheloides des muqueuses. Ann Derm Syph 1906; 7: 151-152
  • 55 Shockman S, Paghdal KV, Cohen G. Medical and surgical management of keloids: a review. J Drugs Dermatol 2010; 9: 1249-1257
  • 56 Ogawa R, Miyashita T, Hyakusoku H, Akaishi S, Kuribayashi S, Tateno A. Postoperative radiation protocol for keloids and hypertrophic scars: statistical analysis of 370 sites followed for over 18 months. Ann Plast Surg 2007; 59: 688-691
  • 57 Ogawa R, Mitsuhashi K, Hyakusoku H, Miyashita T. Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars: retrospective study of 147 cases followed for more than 18 months. Plast Reconstr Surg 2003; 111: 547-553 ; discussion 554–555
  • 58 Malaker K, Vijayraghavan K, Hodson I, Al Yafi T. Retrospective analysis of treatment of unresectable keloids with primary radiation over 25 years. Clin Oncol (R Coll Radiol) 2004; 16: 290-298
  • 59 Apfelberg DB, Maser MR, Lash H, White D, Weston J. Preliminary results of argon and carbon dioxide laser treatment of keloid scars. Lasers Surg Med 1984; 4: 283-290
  • 60 Apfelberg DB, Maser MR, White DN, Lash H. Failure of carbon dioxide laser excision of keloids. Lasers Surg Med 1989; 9: 382-388
  • 61 Bouzari N, Davis SC, Nouri K. Laser treatment of keloids and hypertrophic scars. Int J Dermatol 2007; 46: 80-88
  • 62 Kuo YR, Wu WS, Jeng SF , et al. Activation of ERK and p38 kinase mediated keloid fibroblast apoptosis after flashlamp pulsed-dye laser treatment. Lasers Surg Med 2005; 36: 31-37
  • 63 Kuo YR, Wu WS, Jeng SF , et al. Suppressed TGF-beta1 expression is correlated with up-regulation of matrix metalloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treatment. Lasers Surg Med 2005; 36: 38-42
  • 64 Paquet P, Hermanns J, Pierard GE. Effect of the 585 nm flashlamp-pumped pulsed dye laser for the treatment of keloids. Dermatol Surg 2001; 27: 171
  • 65 Jacob SE, Berman B, Nassiri M, Vincek V. Topical application of imiquimod 5% cream to keloids alters expression genes associated with apoptosis. Br J Dermatol 2003; 149 (Suppl. 66) 62-65
  • 66 Malhotra AK, Gupta S, Khaitan BK, Sharma VK. Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids. Dermatology 2007; 215: 63-65
  • 67 Shridharani SM, Magarakis M, Manson PN, Singh NK, Basdag B, Rosson GD. The emerging role of antineoplastic agents in the treatment of keloids and hypertrophic scars: a review. Ann Plast Surg 2010; 64: 355-361
  • 68 Sanders KW, Gage-White L, Stucker FJ. Topical mitomycin C in the prevention of keloid scar recurrence. Arch Facial Plast Surg 2005; 7: 172-175
  • 69 España A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol Surg 2001; 27: 23-27
  • 70 Xiao Z, Zhang M. Potential therapeutical effects of botulinum toxin type A in keloid management. Med Hypotheses 2008; 71: 623
  • 71 Uyesugi B, Lippincott B, Dave S. Treatment of a painful keloid with botulinum toxin type A. Am J Phys Med Rehabil 2010; 89: 153-155
  • 72 Wendling J, Marchand A, Mauviel A, Verrecchia F. 5-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation. Mol Pharmacol 2003; 64: 707-713
  • 73 Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol 2002; 138: 1149-1155
  • 74 Kontochristopoulos G, Stefanaki C, Panagiotopoulos A , et al. Intralesional 5-fluorouracil in the treatment of keloids: an open clinical and histopathologic study. J Am Acad Dermatol 2005; 52 (3 Pt 1) 474-479
  • 75 Nanda S, Reddy BS. Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol Surg 2004; 30: 54-56 ; discussion 56–57
  • 76 Gupta S, Kalra A. Efficacy and safety of intralesional 5-fluorouracil in the treatment of keloids. Dermatology 2002; 204: 130-132
  • 77 Bodokh I, Brun P. [Treatment of keloid with intralesional bleomycin]. Ann Dermatol Venereol 1996; 123: 791-794
  • 78 Naeini FF, Najafian J, Ahmadpour K. Bleomycin tattooing as a promising therapeutic modality in large keloids and hypertrophic scars. Dermatol Surg 2006; 32: 1023-1029 ; discussion 1029–1030
  • 79 Aggarwal H, Saxena A, Lubana PS, Mathur RK, Jain DK. Treatment of keloids and hypertrophic scars using bleom. J Cosmet Dermatol 2008; 7: 43-49
  • 80 de Oliveira GV, Nunes TA, Magna LA , et al. Silicone versus nonsilicone gel dressings: a controlled trial. Dermatol Surg 2001; 27: 721-726
  • 81 Borgognoni L. Biological effects of silicone gel sheeting. Wound Repair Regen 2002; 10: 118-121